Betamethasone Dipropionate Lotion recalled for unknown impurity
Akorn, Inc. is recalling Betamethasone Dipropionate Lotion USP (Augmented), 0.05%, due to an unknown impurity found in the product that exceeds specification limits. The affected lots were distributed nationwide.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The source text identifies this as an FDA Class II recall. The hazard (unknown impurity out of specification) is present but no illnesses, injuries, or deaths are reported in the source material. This is a quality/purity issue on a topical product without documented harm.
Plain-English summary
Akorn, Inc. is recalling Betamethasone Dipropionate Lotion USP (Augmented), 0.05%, in 30 mL (NDC 61748-480-30) and 60 mL (NDC 61748-480-60) bottles. The product was manufactured by Hi-Tech Pharmacal Co. Inc., Amityville, NY.
The recall was initiated because testing identified an unknown impurity in the lotion that does not meet the product's established specification limits for impurities and degradation. A total of 264 bottles were distributed, including lot 372286 (48 bottles) and lot 372289 (216 bottles), both with an expiration date of 1/31/2022.
The affected product was distributed nationwide in the United States. Consumers who have obtained this product should not use it and should contact their healthcare provider or pharmacist for guidance. This is a prescription product (Rx only).
The recalled product
- Product
- Betamethasone Dipropionate Lotion USP (Augmented), 0.05%, packaged in a) 30 mL bottle (NDC 61748-480-30), b) 60 mL bottle (NDC 61748-480-60), Rx only, Manufactured by: Hi-Tech Pharmacal Co. Inc., Amityville,NY 11701
- Manufacturer
- Akorn, Inc.
- Category
- Drug — Topical Lotion
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lot #: a) 372286
- 372289
- Exp 1/31/2022
- b) 372286
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · Akorn, Inc.
See all →- HighGuaifenesin Oral Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighAkorn Hydromorphone Hydrochloride Injection Recalled Due to CGMP Deviations
FDA (Drugs) · 2023-06-07
- HighFDA Recalls Calcitriol Injection Due to Manufacturing Practice Violations
FDA (Drugs) · 2023-06-07
- HighTobramycin Ophthalmic Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighMidazolam Injection Recalled Due to Manufacturing Compliance and Stability Study Issues
FDA (Drugs) · 2023-06-07
Same hazard · impurity degradation
See all →- Low
- ModerateEsomeprazole Magnesium oral suspension recalled for failed impurity specifications
FDA (Drugs) · 2025-05-28
- HighDiltiazem Hydrochloride extended-release capsules recalled due to failed quality specifications
FDA (Drugs) · 2023-02-08
- ModerateXiidra Ophthalmic Solution Recalled for Failed Impurity and Degradation Specifications
FDA (Drugs) · 2022-06-15
- ModerateXiidra ophthalmic solution recalled for failed impurity and degradation specifications
FDA (Drugs) · 2022-06-15